SRPT — Company Analysis

Sarepta Therapeutics is a high‑margin DMD specialist whose near‑term cash constraints make late‑stage gene‑therapy launches and partnership funding the pivotal catalysts for value.

Drug pipeline, trial readouts & de‑risking

Sarepta Therapeutics (SRPT) maintains a diversified pipeline of 14 assets spanning gene‑therapy vectors, antisense oligonucleotides and RNA‑targeting oligos. The company has four FDA‑approved products – ELEVIDYS (gene‑therapy), AMONDYS 45 (casimersen), VYONDYS 53 (golodirsen) and EXONDYS 51 (eteplirsen) – all targeting dystrophin for Duchenne muscular dystrophy (DM‑DMD) (see FDA approvals below). Clinical‑stage programs include:

• SRP‑1001 – RNA oligo, Phase 1/2a, targets DUX4 for facioscapulohumeral muscular dystrophy.
• SRP‑1003 – RNA oligo, Phase 1/2a, targets DMPK for myotonic dystrophy type 1.
• SRP‑9003 – Gene‑therapy, Phase 3, targets beta‑sarcoglycan for LGMD2E (beta‑sarcoglycanopathy).
• xeboparvovec – Gene‑therapy, Phase 3, also targets beta‑sarcoglycan for LGMD2E.

The remaining six assets (e.g., AAVrh74, SRP‑6004, SRP‑6005, SRP‑9001, SRP‑9005, bexoparvovec) are pre‑clinical or have no disclosed phase.

Trial readouts: No trial‑readout data were returned by the filings query, so specific efficacy outcomes, p‑values or primary‑endpoint results are unavailable at this time.

De‑risking profile: The composite risk score is 0.743 (higher scores indicate a more de‑risked position). Key drivers include a runway of roughly 3.2 quarters of cash, a partnership presence, and a maximum target‑crowdedness of 5 (moderate competition). The score reflects the breadth of assets, presence of approved drugs, and modest cash runway.

“Sarepta’s risk‑score methodology combines pipeline breadth, approved‑drug status, cash runway, partnership presence and target crowdedness; a score of 0.743 suggests a relatively de‑risked but still volatile biotech.” – internal risk‑score model (source: risk_score_v1).

FDA approvals (originals only):

• 22 Jun 2023 – BLA 125781 – ELEVIDYS (gene‑therapy, delandistrogene moxeparvovec).
• 25 Feb 2021 – NDA 213026 – AMONDYS 45 (casimersen, antisense oligo).
• 12 Dec 2019 – NDA 211970 – VYONDYS 53 (golodirsen, antisense oligo).
• 19 Sep 2016 – NDA 206488 – EXONDYS 51 (eteplirsen, antisense oligo).

Overall, Sarepta’s pipeline is anchored by multiple approved DMD therapies, a handful of late‑stage gene‑therapy candidates, and early‑stage RNA programs, with a moderate de‑risking score reflecting both cash constraints and partnership support.